Probiotic Composition Using Exosomes to Relieve Sarcopenia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective medication for treating sarcopenia, a syndrome characterized by progressive skeletal muscle loss and dysfunction, leading to reduced mobility and increased disability in the elderly, and existing nutritional interventions are ineffective due to poor absorption.

Innovation Solution

A probiotic composition comprising Clostridium butyricum M1 and Bacillus coagulans CC212, formulated to promote muscle growth and reduce fat accumulation, utilizing their respective exosomes to activate vitamin B6 and inhibit fat storage, while surviving stomach conditions to germinate in the intestines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If supplementary protein and calories are taken, then muscle mass should increase, but absorption is poor in elderly patients

Engineering Contradiction:

Improvemuscle massVSAvoidabsorption efficiency

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent introduces probiotic bacteria (Lactobacillus acidophilus, Bifidobacterium animalis, and Saccharomyces cerevisiae) as intermediary substances that improve nutrient absorption in elderly patients. These probiotics act as mediators between the digestive system and nutrient absorption, enhancing the body's ability to utilize supplementary protein and calories effectively.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the composition and concentration parameters of probiotic strains to optimize their effectiveness. Specific strain selections and dosage formulations are designed to maximize absorption efficiency while minimizing adverse effects, thereby improving the reliability of nutrient utilization in elderly patients.

Inventive Principle:

Principle #35Parameter changes

2Ease of manufacture

If no medication is available for sarcopenia, then natural diet alone is used, but it is insufficient to effectively relieve sarcopenia

Engineering Contradiction:

Improvesimplicity of interventionVSAvoideffectiveness in relieving sarcopenia

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent combines multiple probiotic strains (Lactobacillus acidophilus, Bifidobacterium animalis, and Saccharomyces cerevisiae) into a single composite formulation. This merging of different microbial species creates a synergistic effect that enhances the overall effectiveness in relieving sarcopenia while maintaining ease of administration as a unified supplement.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent develops a composite probiotic formulation containing multiple bacterial and fungal strains in specific ratios. This composite material approach allows the combination of complementary functions from different organisms to achieve superior efficacy in muscle mass preservation and sarcopenia relief compared to single-strain preparations.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively increases muscle mass and reduces fat accumulation, thereby treating or relieving sarcopenia by enhancing muscle growth and reducing fat storage in subjects.

Implementation Method 1

Clostridium butyricum M1 release a Clostridium butyricum exosome. The Clostridium butyricum exosome includes butyric acid to activate vitamin B6 of the subject, thereby increasing a muscle mass of the subject.

Methodology Applied

Scientific EffectExosome release:

Implementation Method 2

The Clostridium butyricum exosome includes butyric acid to activate vitamin B6 of the subject, thereby increasing a muscle mass of the subject.

Methodology Applied

Scientific EffectVitamin B6 activation:

Implementation Method 3

Bacillus coagulans CC212 releases a Bacillus coagulans exosome; the Bacillus coagulans exosome and the Clostridium butyricum exosome are absorbed by the subject, thereby decreasing a fat mass of the subject.

Methodology Applied

Scientific EffectExosome release:

Implementation Method 4

the Bacillus coagulans exosome and the Clostridium butyricum exosome are absorbed by the subject, thereby decreasing a fat mass of the subject.

Methodology Applied

Scientific EffectAbsorption: Absorption (physical)

Implementation Method 5

the Clostridium butyricum endospores undergo germination and release the Clostridium butyricum exosome.

Methodology Applied

Scientific EffectGermination:

Data Source

PatentUS20250352586A1Compositions for treating and/or relieving sarcopenia and uses thereof

Publication Date: 2025.11.20 SPACE ARK BIOMEDICAL CO LTD

AI summary

A composition for treating and/or relieving sarcopenia includes Clostridium butyricum M1. A microbial number of Clostridium butyricum M1 ranges from 106 CFU/g to 1012 CFU/g. The composition further includes Bacillus coagulans CC212. Bacillus coagulans CC212 is deposited in Bioresource Collection and Research Center. A deposit number of Bacillus coagulans CC212 is BCRC911233. A microbial number of Bacillus coagulans CC212 is ranges from 106 CFU/g to 1012 CFU/g. A use of the composition is to orally administer the composition to a subject. Clostridium butyricum M1 release a Clostridium butyricum exosome. The Clostridium butyricum exosome could promote muscle growth of the subject. Bacillus coagulans CC212 release a Bacillus coagulans exosome. The Bacillus coagulans exosome and the Clostridium butyricum exosome could effectively reduce a fat mass of the subject. Therefore, the subject could experience an increase in muscle mass and a reduction in fat after taking the composition.